blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3503730

EP3503730 - COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.08.2024
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  25.08.2023
FormerGrant of patent is intended
Status updated on  27.03.2023
FormerRequest for examination was made
Status updated on  17.02.2023
FormerGrant of patent is intended
Status updated on  27.09.2022
FormerRequest for examination was made
Status updated on  31.05.2019
FormerThe international publication has been made
Status updated on  03.03.2018
Most recent event   Tooltip25.04.2025Lapse of the patent in a contracting state
New state(s): MC		published on 28.05.2025 [2025/22]
Applicant(s)For all designated states
Dicerna Pharmaceuticals, Inc.
75 Hayden Avenue
Lexington, MA 02421 / US
[2022/30]
Former [2020/37]For all designated states
Dicerna Pharmaceuticals, Inc.
33 Hayden Avenue
Lexington, Massachusetts 02421 / US
Former [2019/27]For all designated states
Dicerna Pharmaceuticals, Inc.
87 Cambridgepark Drive
Cambridge, MA 02140 / US
Inventor(s)01 / WANG, Weimin
c/o Dicerna Pharmaceuticals, Inc.
33 Hayden Avenue
Lexington, MA 02421 / US
02 / KRISHNAMURTHY, Venkata
c/o Dicerna Pharmaceuticals, Inc.
33 Hayden Avenue
Lexington, MA 02421 / US
 [2020/39]
Former [2019/27]01 / WANG, Weimin
C/o Dicerna Pharmaceuticals Inc.
87 Cambridgepark Drive
Cambridge MA 02140 / US
02 / KRISHNAMURTHY, Venkata
C/o Dicerna Pharmaceuticals Inc.
87 Cambridgepark Drive
Cambridge MA 02140 / US
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[2023/39]
Former [2019/27]HGF Limited
8th Floor
140 London Wall
London EC2Y 5DN / GB
Application number, filing date17844358.623.08.2017
[2019/27]
WO2017US48239
Priority number, dateUS201662378635P23.08.2016         Original published format: US 201662378635 P
[2019/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018039364
Date:01.03.2018
Language:EN
[2018/09]
Type: A1 Application with search report 
No.:EP3503730
Date:03.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 01.03.2018 takes the place of the publication of the European patent application.
[2019/27]
Type: B1 Patent specification 
No.:EP3503730
Date:27.09.2023
Language:EN
[2023/39]
Search report(s)International search report - published on:US01.03.2018
(Supplementary) European search report - dispatched on:EP25.08.2020
ClassificationIPC:A01N43/04, A61K31/712, A61K9/107, C07H19/06, C07H21/00, A61P31/12, A61P35/00, A61P35/02
[2020/39]
CPC:
C07H19/06 (EP,IL,US); C12N15/113 (CN,IL,KR,US); C07H19/10 (CN);
A61K31/7072 (CN); A61K31/712 (EP,CN,IL,KR,US); A61K9/107 (IL,US);
A61P1/16 (CN); A61P11/00 (CN); A61P13/12 (CN);
A61P17/00 (CN); A61P25/00 (CN); A61P27/02 (CN);
A61P27/16 (CN); A61P29/00 (CN); A61P3/00 (CN);
A61P31/12 (EP,IL,KR); A61P35/00 (EP,CN,IL); A61P35/02 (EP,CN,IL);
A61P37/06 (CN); C07H1/00 (CN); C07H19/067 (CN);
C07H21/00 (EP,CN,IL,US); C07H21/02 (CN); C07H21/04 (CN);
C12N15/11 (IL,US); C12N15/111 (CN,KR); C12N2310/11 (CN,IL,US);
C12N2310/113 (CN,IL,US); C12N2310/12 (CN,IL,US); C12N2310/14 (CN,IL,KR,US);
C12N2310/141 (CN,IL,US); C12N2310/20 (CN,IL,KR,US); C12N2310/314 (CN,IL,KR,US);
C12N2310/351 (CN,KR); C12N2310/3515 (CN,KR); C12N2310/3519 (CN,KR) (-)
Former IPC [2019/27]A01N43/04, A61K31/712, A61K9/107
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/27]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ZUSAMMENSETZUNGEN MIT REVERSIBEL MODIFIZIERTEN OLIGONUKLEOTIDEN UND VERWENDUNGEN DAVON[2019/27]
English:COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF[2019/27]
French:COMPOSITIONS COMPRENANT DES OLIGONUCLÉOTIDES MODIFIÉS DE MANIÈRE RÉVERSIBLE ET LEURS UTILISATIONS[2019/27]
Entry into regional phase18.03.2019National basic fee paid 
18.03.2019Search fee paid 
18.03.2019Designation fee(s) paid 
18.03.2019Examination fee paid 
Examination procedure18.03.2019Examination requested  [2019/27]
24.02.2021Amendment by applicant (claims and/or description)
28.09.2022Communication of intention to grant the patent
06.02.2023Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.03.2023Communication of intention to grant the patent
03.08.2023Fee for grant paid
03.08.2023Fee for publishing/printing paid
03.08.2023Receipt of the translation of the claim(s)
Opposition(s)28.06.2024No opposition filed within time limit [2024/36]
Fees paidRenewal fee
27.08.2019Renewal fee patent year 03
27.08.2020Renewal fee patent year 04
27.08.2021Renewal fee patent year 05
29.08.2022Renewal fee patent year 06
22.08.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ27.09.2023
ES27.09.2023
HR27.09.2023
MC27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
[2025/22]
Former [2025/20]CZ27.09.2023
ES27.09.2023
HR27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
Former [2024/25]CZ27.09.2023
ES27.09.2023
PL27.09.2023
RO27.09.2023
RS27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
Former [2024/23]CZ27.09.2023
ES27.09.2023
RO27.09.2023
RS27.09.2023
SK27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
Former [2024/20]RS27.09.2023
SM27.09.2023
NO27.12.2023
GR28.12.2023
IS27.01.2024
Former [2024/12]RS27.09.2023
NO27.12.2023
GR28.12.2023
Former [2024/08]NO27.12.2023
GR28.12.2023
Documents cited:Search[A]WO2015032968  (UNIV VIENNA [AT]);
 [A]WO2015069932  (SOLSTICE BIOLOG LTD [IE], et al);
 [A]WO2015188197  (SOLSTICE BIOLOG LTD [IE], et al);
International search[A]US6265558  (COOK PHILLIP DAN [US], et al);
 [A]US9376700  (PETERSSON E JAMES [US]);
by applicantUS20010623934
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.